

David W Ollila

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9158547/david-w-ollila-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

1,794
citations

19
h-index

42
g-index

78
ext. papers

2,328
ext. citations

6.2
avg, IF

4.53
L-index

#	Paper	IF	Citations
73	ASO Visual Abstract: Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	0
72	Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer.. <i>Annals of Surgical Oncology</i> , 2022 , 29, 3051	3.1	0
71	Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy?. <i>American Surgeon</i> , 2022 , 31348211069783	0.8	0
70	Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy.. <i>Journal of the American College of Surgeons</i> , 2022 , 234, 538-545	4.4	0
69	The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.. <i>Npj Breast Cancer</i> , 2022 , 8, 27	7.8	0
68	Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 65	7.8	0
67	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021 , 29, 804	3.1	2
66	Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study.. <i>Current Oncology</i> , 2021 , 28, 4756-4771	2.8	0
65	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	5
64	Disease-Associated Risk Variants in Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2309-2316	4	0
63	Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients?. <i>American Journal of Surgery</i> , 2021 , 221, 706-711	2.7	2
62	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021 , 28, 5960-5971	3.1	5
61	ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies. <i>Annals of Surgical Oncology</i> , 2021 , 28, 5972-5973	3.1	0
60	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). <i>Cancer</i> , 2021 , 127, 2251-2261	6.4	7
59	Effect of Clear vs Standard Covered Masks on Communication With Patients During Surgical Clinic Encounters: A Randomized Clinical Trial. <i>JAMA Surgery</i> , 2021 , 156, 372-378	5.4	22
58	Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3470-3478	3.1	1
57	ASO Visual Abstract: Use and Costs of Sentinel Lymph Node Biopsy in Nonulcerated T1b Melanoma: Analysis of a Population-Based Registry. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3479	3.1	0

56	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021 , 28, 436-437	3.1	
55	Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 509-520	4.4	1
54	An Unusual Case of BIA-ALCL Associated with Prolonged/Complicated Biocell-Textured Expander, followed by Smooth Round Breast Implant Exposure, and Concurrent Use of Adalimumab. <i>Plastic and Reconstructive Surgery</i> , 2021 , 148, 299-303	2.7	3
53	The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 2182-2190	3.1	1
52	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3501-3510	3.1	3
51	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021 , 232, 424-431	4.4	3
50	Gender Bias in Surgical Oncology Fellowship Recommendation Letters: Gaining Progress. <i>Journal of Surgical Education</i> , 2021 , 78, 866-874	3.4	4
49	Direct Comparison of In-Person Versus Virtual Interviews for Complex General Surgical Oncology Fellowship in the COVID-19 Era. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1908-1915	3.1	15
48	Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. <i>Journal of the American College of Surgeons</i> , 2021 , 232, 373-378	4.4	7
47	ASO Author Reflections: The Impact of Virtual Interviews for Complex General Surgical Oncology Fellowship. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1916-1917	3.1	0
46	Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?. <i>American Surgeon</i> , 2021 , 31348211047205	0.8	0
45	Decreased survival and increased recurrence in Merkel cell carcinoma significantly linked with immunosuppression. <i>Journal of Surgical Oncology</i> , 2020 , 122, 653	2.8	6
44	Trends in Surgical Axillary Management in Early Stage Breast Cancer in Elderly Women: Continued Over-Treatment. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3426-3433	3.1	14
43	Use of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. <i>Journal of the American College of Surgeons</i> , 2020 , 230, 515-524	4.4	7
42	High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3556-3556	2.2	0
41	Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 918-922.e7	4.3	1
40	ASO Author Reflections: More Isn't Always Best-Shaping the Dialogue to Decrease Overtreatment of the Axilla in the Elderly. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3434-3435	3.1	2
39	MRI-guided core needle biopsy of the breast: Radiology-pathology correlation and impact on clinical management. <i>Annals of Diagnostic Pathology</i> , 2020 , 48, 151563	2.2	4

38	Reflector Localization of Breast Lesions and Parameters Associated with Positive Surgical Margins in Women Undergoing Breast Conservation Surgery. <i>Journal of Breast Imaging</i> , 2020 , 2, 462-470	1	
37	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. <i>Journal of the American College of Surgeons</i> , 2019 , 228, 644-649	4-4	45
36	Indications for Neoadjuvant Systemic Therapy for Breast Cancer. <i>Advances in Surgery</i> , 2019 , 53, 271-292	1.2	2
35	Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1349-1361	4-3	11
34	Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1410-1412	4-3	
33	Expression of tryptophan metabolizing enzymes (TMEs) and its transporter, LAT1, in metastatic melanoma (MM): Prognostic and therapeutic implications.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e21014-e21014	2.2	2.2
32	High incidence of brain metastases (BrM) in patients with metastatic cutaneous melanoma (MCM) and mutations in the APC/βatenin (CTNNB1).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9527-9527	2.2	
31	Mastectomy May Be an Inferior Oncologic Approach Compared to Breast Preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 78-80	4	6
30	Implementing a Program of Talimogene laherparepvec. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1828-1835	3.1	10
29	Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. <i>British Journal of Cancer</i> , 2018 , 118, 1359-1368	8.7	29
28	Ductal Carcinoma In Situ Simultaneously Involving the Breast and Epithelial Inclusions in an Ipsilateral Axillary Lymph Node. <i>International Journal of Surgical Pathology</i> , 2018 , 26, 564-568	1.2	1
27	The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2807-2812	3.1	7
26	Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 2398-2404	4-3	6
25	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017 , 224, 688-694	4.4	5
24	Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 918-926	27.4	636
23	Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2588-2598	4-3	9
22	Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma. <i>JAMA Dermatology</i> , 2017 , 153, 1026-1031	5.1	15
21	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 297-304	4.4	42

20	Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	23
19	Breast Conservation Therapy Versus Mastectomy: Shared Decision-Making Strategies and Overcoming Decisional Conflicts in Your Patients. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3133-7	3.1	16
18	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2167-76	12.9	12
17	Inherited genetic variants associated with occurrence of multiple primary melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 992-7	4	31
16	Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. <i>JAMA Oncology</i> , 2015 , 1, 359-68	13.4	123
15	Vascular channels formed by subpopulations of PECAM1+ melanoma cells. <i>Nature Communications</i> , 2014 , 5, 5200	17.4	48
14	Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. <i>JAMA Dermatology</i> , 2014 , 150, 1306-314	5.1	101
13	Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. <i>American Journal of Surgery</i> , 2014 , 207, 549-54	2.7	28
12	Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4252-9	2.2	188
11	Metastatic melanoma cells in the sentinel node cannot be ignored. <i>Journal of the American College of Surgeons</i> , 2009 , 208, 924-9; discussion 929-30	4.4	21
10	Sentinel lymph node biopsy controversy: Before or after neoadjuvant chemotherapy. <i>Current Breast Cancer Reports</i> , 2009 , 1, 71-77	0.8	2
9	Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively. <i>Annals of Surgical Oncology</i> , 2007 , 14, 660-9	3.1	32
8	Surgical management of distant metastases. <i>Surgical Oncology Clinics of North America</i> , 2006 , 15, 385-98	2.7	25
7	Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays. <i>American Journal of Surgery</i> , 2006 , 191, 52-6	2.7	33
6	Experienced Radio-Guided Surgery Teams Can Successfully Perform Minimally Invasive Radio-Guided Parathyroidectomy without Intraoperative Parathyroid Hormone Assays. <i>American Surgeon</i> , 2006 , 72, 785-790	0.8	14
5	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. <i>American Journal of Surgery</i> , 2005 , 190, 371-5	2.7	30
4	Tandem BRAF mutations in primary invasive melanomas. <i>Journal of Investigative Dermatology</i> , 2004 , 122, 1245-50	4.3	47
3	Clinical significance of micrometastatic disease in the era of sentinel node. <i>Breast Disease</i> , 2001 , 12, 57-67	1.6	1

- 2 Lymphatic mapping and sentinel lymphadenectomy: critical review of technique. *Breast Disease*, **2001**, 13, 77-84 1.6 1
- 1 Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. *Ca-A Cancer Journal for Clinicians*, **1999**, 49, 101-16, 65 220.7 72